Biovica International AB (publ) (BIOVIC-B.ST)
SEK 0.8
(14.29%)
SEK 0.8
(14.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -124.82 Million SEK | -12.97% |
| 2022 | -110.49 Million SEK | -84.14% |
| 2021 | -60 Million SEK | -51.97% |
| 2020 | -39.48 Million SEK | -30.23% |
| 2019 | -30.31 Million SEK | -40.65% |
| 2018 | -21.55 Million SEK | -19.33% |
| 2017 | -18.06 Million SEK | -21.59% |
| 2016 | -14.85 Million SEK | -195.31% |
| 2015 | -5.03 Million SEK | 28.57% |
| 2014 | -7.04 Million SEK | -31.11% |
| 2013 | -5.37 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -22.88 Million SEK | 42.1% |
| 2023 FY | -124.82 Million SEK | -12.97% |
| 2023 Q3 | -27.34 Million SEK | -6.46% |
| 2023 Q1 | -32.26 Million SEK | 14.42% |
| 2023 Q2 | -25.68 Million SEK | 20.39% |
| 2023 Q4 | -39.53 Million SEK | -44.58% |
| 2022 Q2 | -23.25 Million SEK | -10.69% |
| 2022 FY | -110.49 Million SEK | -84.14% |
| 2022 Q4 | -37.69 Million SEK | -32.1% |
| 2022 Q3 | -28.53 Million SEK | -22.74% |
| 2022 Q1 | -21 Million SEK | -10.22% |
| 2021 Q2 | -14.38 Million SEK | -17.69% |
| 2021 FY | -60 Million SEK | -51.97% |
| 2021 Q1 | -12.22 Million SEK | -1.94% |
| 2021 Q4 | -19.05 Million SEK | -32.94% |
| 2021 Q3 | -14.33 Million SEK | 0.38% |
| 2020 FY | -39.48 Million SEK | -30.23% |
| 2020 Q2 | -8.2 Million SEK | 1.98% |
| 2020 Q3 | -10.9 Million SEK | -32.91% |
| 2020 Q4 | -11.99 Million SEK | -9.93% |
| 2020 Q1 | -8.37 Million SEK | 22.3% |
| 2019 Q2 | -5.95 Million SEK | 2.62% |
| 2019 Q3 | -7.51 Million SEK | -26.13% |
| 2019 Q1 | -6.11 Million SEK | -3.34% |
| 2019 FY | -30.31 Million SEK | -40.65% |
| 2019 Q4 | -10.77 Million SEK | -43.42% |
| 2018 Q1 | -4.02 Million SEK | -7.59% |
| 2018 FY | -21.55 Million SEK | -19.33% |
| 2018 Q4 | -5.92 Million SEK | 2.07% |
| 2018 Q3 | -6.04 Million SEK | -8.66% |
| 2018 Q2 | -5.56 Million SEK | -38.11% |
| 2017 Q2 | -4.65 Million SEK | -33.03% |
| 2017 Q1 | -3.49 Million SEK | 40.97% |
| 2017 FY | -18.06 Million SEK | -21.59% |
| 2017 Q4 | -3.74 Million SEK | 38.79% |
| 2017 Q3 | -6.11 Million SEK | -31.49% |
| 2016 Q3 | -4.05 Million SEK | -48.46% |
| 2016 FY | -14.85 Million SEK | -195.31% |
| 2016 Q4 | -5.92 Million SEK | -46.27% |
| 2016 Q2 | -2.72 Million SEK | -27.12% |
| 2016 Q1 | -2.14 Million SEK | 5.88% |
| 2015 Q4 | -2.28 Million SEK | 0.0% |
| 2015 Q2 | -702.5 Thousand SEK | 0.0% |
| 2015 Q1 | -702.5 Thousand SEK | 0.0% |
| 2015 FY | -5.03 Million SEK | 28.57% |
| 2015 Q3 | -2.28 Million SEK | -224.56% |
| 2014 FY | -7.04 Million SEK | -31.11% |
| 2013 FY | -5.37 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -172.539% |
| Cantargia AB (publ) | -280.02 Million SEK | 55.425% |
| CombiGene AB (publ) | -35.66 Million SEK | -249.983% |
| Cyxone AB (publ) | -22.98 Million SEK | -442.968% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -968.873% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -661.21% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -36.566% |
| Fluicell AB (publ) | -26.55 Million SEK | -370.072% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -1.426% |
| Mendus AB (publ) | -101.61 Million SEK | -22.834% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -236.713% |
| I-Tech AB | 20.2 Million SEK | 717.844% |
| Intervacc AB (publ) | -102.85 Million SEK | -21.362% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -929.213% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1125.746% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -597.452% |
| OncoZenge AB (publ) | -15.9 Million SEK | -684.952% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -28398.402% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 67.843% |
| Lipum AB (publ) | -37.17 Million SEK | -235.744% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 49.787% |
| Ziccum AB (publ) | -21.41 Million SEK | -482.958% |
| BioArctic AB (publ) | 229.24 Million SEK | 154.449% |
| Genovis AB (publ.) | 61.5 Million SEK | 302.964% |
| Camurus AB (publ) | 431.44 Million SEK | 128.932% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 29.811% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -119.678% |
| Aptahem AB (publ) | -11.11 Million SEK | -1023.229% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 59.857% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 30.525% |
| Kancera AB (publ) | -64.88 Million SEK | -92.364% |
| Saniona AB (publ) | -95.81 Million SEK | -30.282% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -195.628% |
| AcouSort AB (publ) | -17.08 Million SEK | -630.429% |
| Xintela AB (publ) | -54.08 Million SEK | -130.799% |
| Abliva AB (publ) | -95.5 Million SEK | -30.692% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2417.545% |
| Amniotics AB (publ) | -30.87 Million SEK | -304.351% |
| 2cureX AB (publ) | -32.51 Million SEK | -283.858% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -873.051% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 73.225% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 84.992% |
| Biosergen AB | -27.03 Million SEK | -361.675% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -655.45% |
| Corline Biomedical AB | -1.8 Million SEK | -6800.111% |
| NextCell Pharma AB | -41.95 Million SEK | -197.482% |
| Nanologica AB (publ) | -75.15 Million SEK | -66.083% |
| LIDDS AB (publ) | -40.2 Million SEK | -210.459% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 61.816% |
| BioInvent International AB (publ) | -330.3 Million SEK | 62.21% |
| SynAct Pharma AB | -215.81 Million SEK | 42.161% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -183.341% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -425.859% |
| Alzinova AB (publ) | -16.48 Million SEK | -657.421% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -14.215% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 49.893% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1157.028% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -10.148% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -491.831% |
| Simris Alg AB (publ) | -37.3 Million SEK | -234.601% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 17.798% |